We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pharma ETFs in Focus on Trump's Drug Price Overhaul
Read MoreHide Full Article
Key Takeaways
President Donald Trump plans to reduce U.S. prescription drug prices by 30% to 80%.
It seeks to align U.S. drug prices with those of the lowest-paying countries globally.
Pharma ETFs like IHE, PPH, PJP, XPH and FTXH are in focus.
President Donald Trump announced plans to sign an executive order aimed at significantly reducing U.S. prescription drug prices by 30% to 80%. The initiative, known as the "most favored nation" policy, seeks to align U.S. drug prices with those of the lowest-paying countries globally.
Trump criticized pharmaceutical companies for charging Americans higher prices, asserting that U.S. consumers often pay three to ten times more for identical drugs compared to patients in other nations. He emphasized that the new pricing structure would not only reduce drug costs domestically but also lead to price increases internationally, aiming to create a more equitable system.
This policy has immediate implications for the pharmaceutical industry and related ETFs. Major pharmaceutical companies like Johnson & Johnson (JNJ), Merck (MRK), Eli Lilly (LLY) and AbbVie (ABBV) saw stock declines following the announcement. Similarly, pharmacy benefit managers such as CVS Health (CVS), Cigna (CI), and UnitedHealth (UNH) saw their shares dip, reflecting concerns over potential revenue impacts.
As such, most pharma ETFs like iShares U.S. Pharmaceuticals ETF (IHE - Free Report) , VanEck Vectors Pharmaceutical ETF (PPH - Free Report) , Invesco Pharmaceuticals ETF (PJP - Free Report) , SPDR S&P Pharmaceuticals ETF (XPH - Free Report) and First Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report) are in focus.
iShares U.S. Pharmaceuticals ETF provides exposure to 37 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. iShares U.S. Pharmaceuticals ETF has $552.1 million in AUM and charges 39 bps in fees and expenses. It trades in average daily volume of 161,000 shares and carries a Zacks ETF Rank #3 (Hold) with a High risk outlook (read: Is Healthcare Losing the Status of Safe Haven? ETFs in Focus).
VanEck Vectors Pharmaceutical ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket. It has amassed $617.8 million in its asset base and charges 36 bps in annual fees. VanEck Vectors Pharmaceutical ETF trades in an average daily volume of 483,000 shares and has a Zacks ETF Rank #3 with a Medium risk outlook.
SPDR S&P Pharmaceuticals ETF provides exposure to pharma companies by tracking the S&P Pharmaceuticals Select Industry Index. With an AUM of $137.3 million, it charges 35 bps in fees a year and trades in an average daily volume of 61,000 shares. It has a Zacks ETF Rank #3 with a High risk outlook.
Invesco Pharmaceuticals ETF offers exposure to companies that are principally engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It follows the Dynamic Pharmaceuticals Intellidex Index and holds 31 stocks in its basket. Invesco Pharmaceuticals ETF has AUM of about $235.3 million and charges 56 bps in fees and expenses. It trades in an average daily volume of 10,000 shares and has a Zacks ETF Rank #3 with a High risk outlook (see: all the Healthcare ETFs here).
First Trust Nasdaq Pharmaceuticals ETF tracks the Nasdaq US Smart Pharmaceuticals Index, holding 50 securities in its basket. It has AUM of $13.7 million and trades in an average daily volume of 15,000 shares. First Trust Nasdaq Pharmaceuticals ETF charges 60 bps in annual fees and has a Zacks ETF Rank #3.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pharma ETFs in Focus on Trump's Drug Price Overhaul
Key Takeaways
President Donald Trump announced plans to sign an executive order aimed at significantly reducing U.S. prescription drug prices by 30% to 80%. The initiative, known as the "most favored nation" policy, seeks to align U.S. drug prices with those of the lowest-paying countries globally.
Trump criticized pharmaceutical companies for charging Americans higher prices, asserting that U.S. consumers often pay three to ten times more for identical drugs compared to patients in other nations. He emphasized that the new pricing structure would not only reduce drug costs domestically but also lead to price increases internationally, aiming to create a more equitable system.
The proposal is expected to face strong pushback once again from drug manufacturers (read: A Look at Pharma ETFs After Strong Q1 Earnings).
Market Impact
This policy has immediate implications for the pharmaceutical industry and related ETFs. Major pharmaceutical companies like Johnson & Johnson (JNJ), Merck (MRK), Eli Lilly (LLY) and AbbVie (ABBV) saw stock declines following the announcement. Similarly, pharmacy benefit managers such as CVS Health (CVS), Cigna (CI), and UnitedHealth (UNH) saw their shares dip, reflecting concerns over potential revenue impacts.
As such, most pharma ETFs like iShares U.S. Pharmaceuticals ETF (IHE - Free Report) , VanEck Vectors Pharmaceutical ETF (PPH - Free Report) , Invesco Pharmaceuticals ETF (PJP - Free Report) , SPDR S&P Pharmaceuticals ETF (XPH - Free Report) and First Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report) are in focus.
iShares U.S. Pharmaceuticals ETF (IHE - Free Report)
iShares U.S. Pharmaceuticals ETF provides exposure to 37 U.S. companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. iShares U.S. Pharmaceuticals ETF has $552.1 million in AUM and charges 39 bps in fees and expenses. It trades in average daily volume of 161,000 shares and carries a Zacks ETF Rank #3 (Hold) with a High risk outlook (read: Is Healthcare Losing the Status of Safe Haven? ETFs in Focus).
VanEck Vectors Pharmaceutical ETF (PPH - Free Report)
VanEck Vectors Pharmaceutical ETF follows the MVIS US Listed Pharmaceutical 25 Index and holds 25 stocks in its basket. It has amassed $617.8 million in its asset base and charges 36 bps in annual fees. VanEck Vectors Pharmaceutical ETF trades in an average daily volume of 483,000 shares and has a Zacks ETF Rank #3 with a Medium risk outlook.
SPDR S&P Pharmaceuticals ETF (XPH - Free Report)
SPDR S&P Pharmaceuticals ETF provides exposure to pharma companies by tracking the S&P Pharmaceuticals Select Industry Index. With an AUM of $137.3 million, it charges 35 bps in fees a year and trades in an average daily volume of 61,000 shares. It has a Zacks ETF Rank #3 with a High risk outlook.
Invesco Pharmaceuticals ETF (PJP - Free Report)
Invesco Pharmaceuticals ETF offers exposure to companies that are principally engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It follows the Dynamic Pharmaceuticals Intellidex Index and holds 31 stocks in its basket. Invesco Pharmaceuticals ETF has AUM of about $235.3 million and charges 56 bps in fees and expenses. It trades in an average daily volume of 10,000 shares and has a Zacks ETF Rank #3 with a High risk outlook (see: all the Healthcare ETFs here).
First Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report)
First Trust Nasdaq Pharmaceuticals ETF tracks the Nasdaq US Smart Pharmaceuticals Index, holding 50 securities in its basket. It has AUM of $13.7 million and trades in an average daily volume of 15,000 shares. First Trust Nasdaq Pharmaceuticals ETF charges 60 bps in annual fees and has a Zacks ETF Rank #3.